Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma
NCT04557956Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in melanoma, sponsored by National Cancer Institute. Started Aug 2021; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04557956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557956.